SAIRIYO THERAPEUTICS
Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration ("FDA") approval.
SAIRIYO THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care
Address:
Toronto, Ontario, Canada
Country:
Canada
Status:
Active
More informations about "Sairiyo Therapeutics"
Sairiyo Therapeutics - Crunchbase Company Profile & Funding
Sairiyo Therapeutics is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds.See details»
Sairiyo Therapeutics 2025 Company Profile: Valuation, Investors ...
Information on acquisition, funding, investors, and executives for Sairiyo Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Sairiyo Therapeutics - Pharmadrug Inc
Sairiyo Therapeutics is focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain FDA and EMA drug approval.See details»
Recent Post - Pharmadrug Inc
Sairiyo’s wholly-owned subsidiary in Australia, Sairiyo Therapeutics Australia Pty Ltd., will work with an Australian clinical research unit to submit the clinical and regulatory package to the …See details»
PharmaDrug Completes Acquisition of Sairiyo Therapeutics Inc.
Feb 2, 2021 Sairiyo has an exclusive license from a research and development organization to develop and commercialize reformulated Cepharanthine for all diseases and exclusive rights …See details»
Pharmadrug Inc
PharmaDrug owns 51% of Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them …See details»
PharmaDrug's Sairiyo Therapuetics Announces Initiation of
Sep 19, 2024 PharmaDrug owns 51% of Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of …See details»
PharmaDrug Completes Acquisition of Sairiyo Therapeutics Inc.
Feb 2, 2021 Sairiyo has an exclusive license from a research and development organization to develop and commercialize reformulated Cepharanthine for all diseases and exclusive rights …See details»
PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo ...
Jan 25, 2021 Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening …See details»
PharmaDrug's Sairiyo Therapeutics Announces Successful …
Oct 31, 2024 As announced on August 19, 2024, Sairiyo Therapeutics Inc. ("Sairiyo"), a company that is fifty-one percent (51%) owned by PharmaDrug and fourty-nine percent (49%) …See details»
PharmaTher’s Sairiyo Therapeutics Receives Approval to
Aug 19, 2024 Sairiyo Therapeutics Inc., which is owned by PharmDrug Inc. (51%) and PharmaTher (49%), is focused on advancing the clinical development of an improved and …See details»
Recent Post - Pharmadrug Inc
PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc. Toronto, Ontario – July 18, 2023 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“ PharmaDrug ” or the “ …See details»
PharmaDrug Announces LOI to Acquire Sairiyo Therapeutics Inc.
Jan 12, 2021 In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti …See details»
Sairiyo Therapeutics - Products, Competitors, Financials, …
About Sairiyo Therapeutics Sairiyo Therapeutics is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, …See details»
PharmaDrug's Sairiyo Successfully Demonstrates Ability to …
Toronto, Ontario--(Newsfile Corp. - February 14, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused …See details»
PharmaTher’s Sairiyo Therapeutics Completes Clinical and
May 1, 2024 Sairiyo's wholly-owned subsidiary in Australia, Sairiyo Therapeutics Australia Pty Ltd., will work with an Australian clinical research unit to submit the clinical and regulatory …See details»
Recent Post - Pharmadrug Inc
PharmaDrug owns 51% of Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them …See details»
PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo ...
Jan 25, 2021 Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases. Sairiyo recently received FDA orphan drug …See details»
Recent Post - Pharmadrug Inc
PharmaDrug’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine Toronto, Ontario – May 15, 2024 – PharmaDrug Inc. …See details»
Press Releases Ketamine - PharmaTher Holdings Ltd. Ketamine
May 1, 2024 Sairiyo's wholly-owned subsidiary in Australia, Sairiyo Therapeutics Australia Pty Ltd., will work with an Australian clinical research unit to submit the clinical and regulatory …See details»